Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 5Gastrointestinal Stromal Tumors 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Liver Neoplasms 4Ovarian Neoplasms 2Melanoma 2Cholangiocarcinoma 2Wilms Tumor 1Uveal Melanoma 1Uterine Neoplasms 1Stomach Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Retinoblastoma 1Prostatic Neoplasms 1Pinealoma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Meningeal Neoplasms 1Medulloblastoma 1Liver Diseases 1Liver Cirrhosis 1Klatskin Tumor 1Hepatoblastoma 1Hepatitis D 1Hepatitis B 1

Interventions

zanidatamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × HER2-Positive Advanced Biliary Tract Cancer × Gastrointestinal × Clear all
NCT04578444 2025-05-25

An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer

Jazz Pharmaceuticals

No longer available
Gastrointestinal

HER2-Positive Advanced Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡